Janus Henderson Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Janus Henderson Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.7M	Buy	3,784,055 +54,396	+1%	+$729K	0.02%	425
2025 Q4	$58.8M	Buy	3,729,659 +1,782,745	+92%	+$22.6M	0.03%	383
2025 Q3	$23.3M	Buy	1,946,914 +1,423,171	+272%	+$11.4M	0.01%	579
2025 Q2	$3.96M	Buy	+523,743	New	+$3.15M	﹤0.01%	979
2023 Q2	–	Sell	-8,452	Closed	-$341K	–	2618
2023 Q1	$341K	Buy	+8,452	New	+$404K	﹤0.01%	2221
2022 Q2	–	Sell	-3,686	Closed	-$262K	–	2623
2022 Q1	$262K	Buy	3,686 +2	+0.1%	+$130	﹤0.01%	2301
2021 Q4	$276K	Buy	+3,684	New	+$289K	﹤0.01%	2237
2020 Q1	–	Sell	-641,818	Closed	-$39.7M	–	1323
2019 Q4	$39.7M	Sell	641,818 -223,491	-26%	-$13.9M	0.02%	663
2019 Q3	$52M	Sell	865,309 -79,478	-8%	-$5.9M	0.03%	565
2019 Q2	$79.7M	Buy	944,787 +70,390	+8%	+$6.33M	0.04%	447
2019 Q1	$83.5M	Buy	874,397 +126,804	+17%	+$11.4M	0.05%	440
2018 Q4	$53M	Buy	747,593 +620,983	+490%	+$47.6M	0.03%	522
2018 Q3	$10.8M	Sell	126,610 -9	-0%	-$902	0.01%	920
2018 Q2	$14.7M	Sell	126,619 -367,679	-74%	-$36.7M	0.01%	864
2018 Q1	$40M	Buy	+494,298	New	+$38M	0.02%	608

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's ENTA Position: Q1 2026 in Review

Janus Henderson Group increased its Enanta Pharmaceuticals (ENTA) stake by 1.5% in Q1 2026, buying an estimated $729K and bringing the position to 3,784,055 shares worth $47.7M. The position accounts for 0.02% of the portfolio, ranked #425.

Janus Henderson Group first reported a position in ENTA in Q1 2018 and has held it in 15 quarters since. The position peaked at $83.5M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Janus Henderson Group held 3,784,055 shares of Enanta Pharmaceuticals worth $47.7M as of Q1 2026.
Janus Henderson Group bought 54,396 Enanta Pharmaceuticals shares in Q1 2026, an estimated $729K.
Enanta Pharmaceuticals made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #425 holding.
Janus Henderson Group first reported a position in Enanta Pharmaceuticals in Q1 2018 and has held it in 15 quarters since.
Janus Henderson Group's Enanta Pharmaceuticals position peaked at $83.5M in Q1 2019.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.